Advancing regenerative medicine: Cellbricks Therapeutics reaches key milestone using Rousselot biomaterials

28 August 2025 -- Son, the Netherlands and Berlin, Germany -- Rousselot, Darling Ingredients’ premier collagen and gelatin brand, announces promising preclinical results from a study conducted by Cellbricks Therapeutics, a Berlin-based biotech startup and spin-off from the Technical University of Berlin. As a pioneer in 3D-bioprinting, Cellbricks successfully implanted 3D-bioprinted adipose tissue constructs into mice, with no signs of fibrosis or rejection observed after seven weeks.

A key hurdle in regenerative medicine is achieving transplanted cell survival and integration with host tissues while minimizing immune responses. To address this, Cellbricks incorporated Rousselot’s medical-grade biomaterials – specifically, purified gelatins – which played a pivotal role in enhancing both the structural and functional performance of the bioink used in the constructs.

“The purity, consistency and biocompatibility of Rousselot gelatin were key to the success of our project,” said Alexander Thomas, Soft Tissue Program Leader at Cellbricks. “We observed rapid tissue integration and vascularization that led to the formation of viable fatty tissue in the constructs — key indicators of successful long-term grafting.”

Tanja Vervust, Global Director Biomedical at Rousselot, added “Cellbricks’ pioneering work in organ and tissue printing, combined with Rousselot’s high-quality biomaterials, can represent a significant step forward in regenerative medicine. This achievement reflects how collaboration around medical-grade biomaterials and advanced bioprinting can accelerate progress in tissue engineering, delivery of cell therapies, and organ printing.”

Rousselot continues to play a key role in advancing regenerative therapies by providing innovators like Cellbricks with high-performance biomaterials that enable new possibilities in the field.

About Rousselot
With over 130 years of expertise, 16 production facilities spanning eight countries across four continents and a robust global sales network, Rousselot pushes the limits of innovation by delivering standard and tailored collagen and gelatin solutions to support customer success while maintaining the highest industry standards. Visit: darlingii.com/en/rousselot/about.

About Cellbricks Therapeutics
Cellbricks Therapeutics is a Berlin and Boston-based preclinical biotech company pioneering the future of regenerative medicine and longevity. Built on deep tech innovation, the company combines proprietary biofabrication technology with advanced biomaterials and human cells to develop implantable tissue grafts for clinical use. Cellbricks’ mission is to transform healthcare by restoring tissue function – reliably and at scale. Visit: cellbricks-therapeutics.com